Lonza expands microbial capacity and extends partnership with Servier for L-asparaginase API manufacturing
![](/46/pdcnewsitem/08/43/27/visp%20(1).jpg)
Lonza's Visp, Switzerland, site.
New mid-scale microbial facility will support Servier with API for acute lymphoblastic leukemia therapies.
Lonza's microbial manufacturing facility in Visp, Switzerland is poised for expansion so that it can provide mid-scale commercial manufacturing to multiple customers and serve the growing needs of Servier, an independent international pharmaceutical company and long-term Lonza partner.
Servier and Lonza have signed a long-term extension to the manufacturing agreement for L-asparaginase, produced at Lonza since 2009.
The extension and expansion of the collaboration will provide Servier with the additional capacity required to provide treatment to many more patients with acute lymphoblastic leukemia (ALL), a cancer of the white blood cells.
Servier intends to expand access to asparaginase-based multi-agent chemotherapeutic regimens, as ALL continues to be the most common type of cancer among children diagnosed with leukemia.
The new facility will be the sixth to be housed in Lonza’s new biopark in Visp, Switzerland, currently under construction.
The new mid-scale (3,000 L) microbial facility will tap into existing central utilities and labs and will complement the existing small-scale (1,000 L) and large-scale (15,000 L) assets in Visp. The facility is expected to be operational in the second half of 2022 and Lonza expects to add 100 new staff to the existing, highly-experienced microbial team.
Traditionally used for producing hormones, enzymes and some vaccines, microbial fermentation is becoming increasingly attractive for new molecular formats that do not need human glycosylation given the higher yields and shorter production timelines. For example, many antibody fragments, as well as plasmid DNA, can be produced in microbial systems.
Jean-Christoph Hyvert, Chief Commercial Officer, Lonza said: "We see a clear role for microbial technology as new medicines evolve and we are investing in key enablers including expression technology and manufacturing assets.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance